



UNRELATED NEWS

BUT SOME COULD BE IMPACTING

The recent news that could have impact, temporary or long-term touches on stock movements based on a competitor's performance. What we are referring to is **Tercica's (TRCA)** stock dive because **Insmmed (INSM)** was granted FDA approval for its competing drug Iplex. The newly approved drug is based on IGF- 1, which **when missing in some children, growth hormone treatment will not help their short stature**. Of course INSM surged. One has to recognize the fact, though, that the IGF-1 deficiency is not common and the cases are rare, that's why the orphan drug designation. We have to remind ourselves, however, that rare cases do not mean that the treatments will not generate large revenues. We took the lesson from Genzyme substitution, small market, therapies, which made up the glory of the firm.

CURAGEN (CRGN)

Recent news announced results of CuraGen's drug for oral mucositis – a mouth complication of cancer treatments. Investors took them as a setback for the drug and initiated a sell-off of the firm's stock.

Read the news : [CuraGen Announces Preliminary Top-line Phase II Results on Velafermin](#)

We believe that the selloff of the stock and further selling will turn it into a **big investment opportunity**. First, the power of this firm is in the genomics area and this drug is an outsider, or a plus. (by the way the results are no condemnation for the drug) **Other news announced today highlights our aforementioned remarks**. The news announced that CuraGen's subsidiary 454 Life science was picked up for an extremely important genomics project

Read the news [NCGR Collaborates with the Ohio State University, DOE Joint Genome Institute, University of Tennessee and 454 Life Sciences to Sequence the Genome of the Major Pathogen of Vegetable Crops](#)

ANADYS (ANDS)

In other news about a technology that we believe will take the biotech drug business into a much higher level, i.e **Toll-Like Receptor**, we read that **Anadys Pharmaceuticals** has selected novel oral Toll-Like Receptor ligand as candidate for cancer treatment. This is a large step forward (Read Prohost monthly and weekly reports to know who's who in the Toll-Like Receptor drug development). Here is today's news on the topic if you are interested. .

Read [Anadys Pharmaceuticals Selects a Novel Oral Toll-Like Receptor Ligand as Drug Development Candidate for Cancer](#)

BIOSANTE (BPA)

An opinion about BioSante from Dutton Associates [Dutton Associates Announces Investment Opinion: BioSante Speculative Buy Rating and \\$10 Target Maintained in Update by Dutton Associates](#)

IMMUNOGEN (IMGN)

When **Genentech (DNA)** chooses, investors listen and the firms that Genentech select to do business with are definitely rewarded. **ImmunoGen (IMGN)** is the star in this news.

Read [ImmunoGen, Inc. Announces Genentech Has Taken Fourth License to Use ImmunoGen's TAP Technology to Develop Novel Anticancer Therapeutics](#)



PROHOST RESEARCH
P.O.BOX 640 429
Oakland Gardens, NY 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>